Patents by Inventor Lee A. Flippin

Lee A. Flippin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160009653
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoictin-associated conditions.
    Type: Application
    Filed: September 21, 2015
    Publication date: January 14, 2016
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Cyanoisoquinoline compounds and methods of use thereof
    Patent number: 9174976
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: November 3, 2015
    Assignee: FIBROGEN, INC.
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Thiochromene derivatives as HIF hydroxylase inhibitors
    Patent number: 9149476
    Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: October 6, 2015
    Assignee: FIBROGEN, INC.
    Inventors: Wen-Bin Ho, Lee A. Flippin, Craig Mossman, Eric D. Turtle, Lee R. Wright
  • ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY
    Publication number: 20150209336
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Application
    Filed: January 29, 2015
    Publication date: July 30, 2015
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS
    Publication number: 20150182528
    Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: December 24, 2014
    Publication date: July 2, 2015
    Inventors: Wen-Bin Ho, Lee A. Flippin, Craig Mossman, Eric D. Turtle, Lee R. Wright
  • NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20150174110
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: December 23, 2014
    Publication date: June 25, 2015
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • Thienopyridine compounds, and methods of use thereof
    Patent number: 9000006
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: April 7, 2015
    Assignee: Fibrogen, Inc.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20150080425
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: July 16, 2014
    Publication date: March 19, 2015
    Applicant: FibroGen, Inc.
    Inventors: STEPHEN J. KLAUS, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
    Patent number: 8952160
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: February 10, 2015
    Assignee: Fibrogen, Inc.
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS
    Publication number: 20150038528
    Abstract: The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 5, 2015
    Inventors: Wen-Bin Ho, Hongda Zhao, Shaojiang Deng, Danny Ng, Lee R. Wright, Min Wu, Xiaoti Zhou, Michael P. Arend, Lee A. Flippin
  • CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20150031696
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Application
    Filed: May 28, 2014
    Publication date: January 29, 2015
    Applicant: FIBROGEN, INC.
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Thiochromene derivatives as HIF hydroxylase inhibitors
    Patent number: 8927591
    Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: January 6, 2015
    Assignee: Fibrogen, Inc.
    Inventors: Wen-Bin Ho, Lee R. Wright, Eric D. Turtle, Craig Mossman, Lee A. Flippin
  • Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
    Patent number: 8921389
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: December 30, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8916585
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: December 23, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20140343094
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: May 21, 2014
    Publication date: November 20, 2014
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF
    Publication number: 20140221422
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: FIBROGEN, INC.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8765956
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: July 1, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Cyanoisoquinoline compounds and methods of use thereof
    Patent number: 8759373
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: June 24, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Thienopyridine compounds, and methods of use thereof
    Patent number: 8703795
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: April 22, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20140088101
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: February 1, 2012
    Publication date: March 27, 2014
    Applicant: FibroGen, Inc.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin